Patents Assigned to Allele Biotechnology & Pharmaceuticals, Inc.
  • Patent number: 10842728
    Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: November 24, 2020
    Assignee: Allele Biotechnology & Pharmaceuticals, Inc.
    Inventor: Jiwu Wang
  • Patent number: 10435711
    Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: October 8, 2019
    Assignee: Allele Biotechnology & Pharmaceuticals, Inc.
    Inventor: Jiwu Wang
  • Patent number: 10221221
    Abstract: The present disclosure provides isolated nucleic acid sequences encoding a monomeric green/yellow fluorescent proteins, and fragments and derivatives thereof. Also provided is a method for engineering the nucleic acid sequence, a vector comprising the nucleic acid sequence, a host cell comprising the vector, and use of the vector in a method for expressing the nucleic acid sequence. The present invention further provides an isolated nucleic acid, or mimetic or complement thereof, that hybridizes under stringent conditions to the nucleic acid sequence. Additionally, the present invention provides a monomeric green/yellow fluorescent protein encoded by the nucleic acid sequence, as well as derivatives, fragments, and homologues thereof. Also provided is an antibody that specifically binds to the green/yellow fluorescent protein.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: March 5, 2019
    Assignee: ALLELE BIOTECHNOLOGY & PHARMACEUTICALS, INC
    Inventors: Nathan C. Shaner, Gerard G. Lambert, Yuhui Ni, Jiwu Wang
  • Publication number: 20190017019
    Abstract: A novel method of inducing neural progenitor cells, oligodendrocyte progenitor cells, oligodendrocytes from human iPSCs at an unprecedented efficiency and functionality. The core of the invention is the use of experimentally discovered transcription factors at multiple critical differentiation decision points along a pluripotent to ectoderm, neural ectoderm to NPCs to OPCs to oligodendrocytes pathway in a previously unknown manner.
    Type: Application
    Filed: July 13, 2018
    Publication date: January 17, 2019
    Applicant: Allele Biotechnology and Pharmaceuticals, Inc.
    Inventors: Jiwu WANG, Yuhui NI, Yuanyuan ZHAO
  • Patent number: 10155929
    Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: December 18, 2018
    Assignee: ALLELE BIOTECHNOLOGY & PHARMACEUTICALS, INC.
    Inventors: Jiwu Wang, Luigi Warren, Yuhui Ni
  • Patent number: 10119150
    Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: November 6, 2018
    Assignee: Allele Biotechnology & Pharmaceuticals, Inc.
    Inventor: Jiwu Wang
  • Patent number: 9737472
    Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: August 22, 2017
    Assignee: ALLELE BIOTECHNOLOGY & PHARMACEUTICALS, INC.
    Inventor: Jiwu Wang
  • Patent number: 9205284
    Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: December 8, 2015
    Assignee: Allele Biotechnology & Pharmaceuticals, Inc.
    Inventor: Jiwu Wang
  • Patent number: 9145447
    Abstract: The present disclosure provides an isolated nucleic acid sequence encoding a monomeric photoconvertible fluorescent protein, and fragments and derivatives thereof. Also provided is a method for engineering the nucleic acid sequence, a vector comprising the nucleic acid sequence, a host cell comprising the vector, and use of the vector in a method for expressing the nucleic acid sequence. The present disclosure further provides an isolated nucleic acid, or mimetic or complement thereof, that hybridizes under stringent conditions to the nucleic acid sequence. Additionally, the present provides a monomeric photoconvertible fluorescent protein encoded by the nucleic acid sequence, as well as derivatives, fragments, and homologues thereof. Also provided is an antibody that specifically binds to the photoconvertible fluorescent protein.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: September 29, 2015
    Assignees: Allele Biotechnology & Pharmaceuticals, Inc., University of Alberta, TEC Edmonton
    Inventors: Jiwu Wang, Robert Earl Campbell, Hiofan Hoi, Nathan Christopher Shaner
  • Publication number: 20140349401
    Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.
    Type: Application
    Filed: May 30, 2014
    Publication date: November 27, 2014
    Applicant: Allele Biotechnology & Pharmaceuticals, Inc.
    Inventor: Jiwu WANG
  • Patent number: 7625750
    Abstract: DNA compositions that mediate gene silencing via RNA interference are provided. The DNA compositions include an RNA polymerase III promoter, which drives expression of a nucleotide sequence encoding an intermediate small interfering RNA molecule, and RNA polymerase III terminator.
    Type: Grant
    Filed: December 26, 2002
    Date of Patent: December 1, 2009
    Assignee: Allele Biotechnology & Pharmaceuticals, Inc.
    Inventor: Jiwu Wang
  • Patent number: 7422896
    Abstract: DNA compositions that mediate gene silencing via RNA interference are provided. The DNA compositions include an RNA polymerase III promoter, which drives expression of a nucleotide sequence encoding an intermediate small interfering RNA molecule, and RNA polymerase III terminator.
    Type: Grant
    Filed: August 12, 2002
    Date of Patent: September 9, 2008
    Assignee: Allele Biotechnology & Pharmaceuticals, Inc.
    Inventor: Jiwu Wang
  • Patent number: 7294504
    Abstract: DNA compositions that mediate gene silencing via RNA interference are provided. Also provided are methods of using such compositions to silence gene expression in a cell.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: November 13, 2007
    Assignee: Allele Biotechnology & Pharmaceuticals, Inc.
    Inventor: Jiwu Wang
  • Publication number: 20050042603
    Abstract: Compositions that increase the efficiency of nucleic acid transfection of cells are provided, including peptide transfection reagents and fusion proteins containing the peptides. Also provided are methods of using the peptide transfection reagents and fusion proteins to transfect cells.
    Type: Application
    Filed: June 29, 2004
    Publication date: February 24, 2005
    Applicant: Allele Biotechnology & Pharmaceuticals, Inc.
    Inventor: Jiwu Wang